Global Amebiasis Drugs

Amebiasis Drugs Comprehensive Study by Type (Branded Drugs, Generic Drugs), Infection Type (Bone Infection, Skin Infection, Ent Infections, Gastrointestinal Infection, Surgical Site Infections, Bloodstream Infections, Others), Distribution Channel (Online Pharmacies, Retail Pharmacies, Hospital Pharmacies), Site of Action (Luminal Amebicides, Systemic Amebicides, Mixed (Luminal and Systemic) Amebicides) Players and Region - Global Market Outlook to 2027

Amebiasis Drugs Market by XX Submarkets | Forecast Years 2020-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Amebiasis Drugs?
Amebicide is a kind of anti-infective drug. Amebicides are agents that kill or destroy amebae. Every amebicide features a totally different mode of action. Amebicides are used for the destruction of parasitic species of amebae in humans or animals. Amebicides are used for the treatment of various infectious diseases like amebiasis. Amebiasis is an infection that's caused by Entamoeba histolytica. Entamoeba histolytica infects the internal organ tract of humans or animals. Amebicide medicine is given orally or intravenously. The absorption of an amebicide drug is complete and rapid. Due to speedy absorption through the gastrointestinal tract, these medicines are less effective against parasites within the lumen. Amebicide medicine is distributed to all tissues and body fluids like milk, saliva, and cerebrospinal fluid. An amebicide drug is metabolized by oxidization within the liver by a mixed-function enzyme, followed by glucuronidation. The drug is excreted within the urine as an unchanged drug and matter. Amebicide medicine will cause sure adverse effects such as oral thrush, diarrhea, metallic taste, dry mouth, vomiting, or nausea.

AttributesDetails
Study Period2015-2027
Base Year2019
UnitValue (USD Million)
Key Companies ProfiledDr. Reddy's Laboratories (India), Mission Pharmacal (United States), Aceto Corporation (United States), Mylan Pharmaceuticals (United States), Impax Laboratories (United States), Pfizer (United States), Sanofi (France), Lupin Pharmaceuticals (India), Glenmark Pharmaceuticals (India), Sun Pharmaceutical (India) and Heritage Pharmaceuticals (United States)


The study covers a detailed analysis segmented by key business segments i.e. by type (Branded Drugs and Generic Drugs) and major geographies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Amebiasis Drugs market throughout the predicted period.

The competition is expected to become even more intense in the years to come due to the entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this Amebiasis Drugs market report suggests strategies that Players can follow and highlights key areas they should focus on, in order to take maximum benefits of growth opportunities.

The report offers several leading Players, some of them are Dr. Reddy's Laboratories (India), Mission Pharmacal (United States), Aceto Corporation (United States), Mylan Pharmaceuticals (United States), Impax Laboratories (United States), Pfizer (United States), Sanofi (France), Lupin Pharmaceuticals (India), Glenmark Pharmaceuticals (India), Sun Pharmaceutical (India) and Heritage Pharmaceuticals (United States).

Market Overview:
In February 2022, Dr Reddy's Laboratories on Thursday said it has inked a pact to acquire Germany-based Nimbus Health GmbH. Dr Reddy's Laboratories on Thursday said it has inked a pact to acquire Germany-based Nimbus Health GmbH. The acquisition will allow Dr Reddy has to build on Nimbus Health's strengths and introduce medical cannabis-based medicines as a promising treatment option for patients, it added.
TITLE 21--FOOD AND DRUGS CHAPTER I--FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES SUBCHAPTER H - MEDICAL DEVICES PART 866 -- IMMUNOLOGY AND MICROBIOLOGY DEVICES Subpart D - Serological Reagents Sec. 866.3220 Entamoeba histolytica serological reagents. (b) Classification: Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 866.9.
The geriatric population is more prone to infections due to their low immunity levels. Infections, especially parasitic, are becoming increasingly common among elderly people. The growth of the market in the region is attributable to developing infrastructure, growing awareness, and increasing purchasing power of people.

Amebiasis Drugs Market Dynamics:
AttributesDetails
Growth Drivers
  • Increasing Prevalence of Parasitic Infections
  • The Increasing Pool of Patients Suffering from Amebic Infections
Major Trends
  • The Rising Level of Awareness
  • Better Treatment Facilities
Restraints
  • High Cost of New Drugs
Road Blocks / Challenges
  • Presence Of Unfavourable Reimbursement Policies
Gaps & Opportunities
  • Continued Launch of Effective Drugs


Key highlights of the Global Amebiasis Drugs market Study:
• CAGR of the market during the forecast period 2019-2027
• In-depth information on growth factors that will accelerate the Amebiasis Drugs market in next few years.
• Detailed Insights on futuristic trends and changing consumer behavior
• Forecast of the Global Amebiasis Drugs market size and its contribution to the parent market by type, application and by country.
• A broad view of customer demand
• Uncover market’s competitive landscape and in-depth information on various Players
• Comprehensive information about factors that will challenge the growth of Amebiasis Drugs Players

Transformation and Important Triggers:
Business transformation has taken hold across the broad corporate landscape due to the confluence of several important triggers, including:
• A tipping point in globalization
• A major slowdown in Western economies
• Significant shifts in technology and cost structure
• The challenges of regulatory compliance
• New forms of competition developing

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Amebiasis Drugs market.
In order to reach an exhaustive list of functional and relevant players, various industry classification standards are closely followed such as NAICS, ICB, and SIC to penetrate deep into important geographies by players, and a thorough validation test is conducted to reach the most relevant players for survey in Amebiasis Drugs market.
In order to make a priority list sorting is done based on revenue generated based on the latest reporting, using paid databases such as Factiva, Bloomberg, etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes Manufacturers of Amebiasis Drugs, Suppliers and distributors of Amebiasis Drugs, Governmental and Regulatory bodies and End-Users.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth, etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that include Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases, etc.

Report Objectives / Segmentation Covered

By Type
  • Branded Drugs
  • Generic Drugs
By Infection Type
  • Bone Infection
  • Skin Infection
  • Ent Infections
  • Gastrointestinal Infection
  • Surgical Site Infections
  • Bloodstream Infections
  • Others

By Distribution Channel
  • Online Pharmacies
  • Retail Pharmacies
  • Hospital Pharmacies

By Site of Action
  • Luminal Amebicides
  • Systemic Amebicides
  • Mixed (Luminal and Systemic) Amebicides

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Parasitic Infections
      • 3.2.2. The Increasing Pool of Patients Suffering from Amebic Infections
    • 3.3. Market Challenges
      • 3.3.1. Presence Of Unfavourable Reimbursement Policies
    • 3.4. Market Trends
      • 3.4.1. The Rising Level of Awareness
      • 3.4.2. Better Treatment Facilities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Amebiasis Drugs, by Type, Infection Type, Distribution Channel, Site of Action and Region (value and price ) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Amebiasis Drugs (Value)
      • 5.2.1. Global Amebiasis Drugs by: Type (Value)
        • 5.2.1.1. Branded Drugs
        • 5.2.1.2. Generic Drugs
      • 5.2.2. Global Amebiasis Drugs by: Infection Type (Value)
        • 5.2.2.1. Bone Infection
        • 5.2.2.2. Skin Infection
        • 5.2.2.3. Ent Infections
        • 5.2.2.4. Gastrointestinal Infection
        • 5.2.2.5. Surgical Site Infections
        • 5.2.2.6. Bloodstream Infections
        • 5.2.2.7. Others
      • 5.2.3. Global Amebiasis Drugs by: Distribution Channel (Value)
        • 5.2.3.1. Online Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Hospital Pharmacies
      • 5.2.4. Global Amebiasis Drugs by: Site of Action (Value)
        • 5.2.4.1. Luminal Amebicides
        • 5.2.4.2. Systemic Amebicides
        • 5.2.4.3. Mixed (Luminal and Systemic) Amebicides
      • 5.2.5. Global Amebiasis Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Amebiasis Drugs (Price)
      • 5.3.1. Global Amebiasis Drugs by: Type (Price)
  • 6. Amebiasis Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Dr. Reddy's Laboratories (India)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Mission Pharmacal (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Aceto Corporation (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Mylan Pharmaceuticals (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Impax Laboratories (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sanofi (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Lupin Pharmaceuticals (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Glenmark Pharmaceuticals (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sun Pharmaceutical (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Heritage Pharmaceuticals (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Amebiasis Drugs Sale, by Type, Infection Type, Distribution Channel, Site of Action and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Amebiasis Drugs (Value)
      • 7.2.1. Global Amebiasis Drugs by: Type (Value)
        • 7.2.1.1. Branded Drugs
        • 7.2.1.2. Generic Drugs
      • 7.2.2. Global Amebiasis Drugs by: Infection Type (Value)
        • 7.2.2.1. Bone Infection
        • 7.2.2.2. Skin Infection
        • 7.2.2.3. Ent Infections
        • 7.2.2.4. Gastrointestinal Infection
        • 7.2.2.5. Surgical Site Infections
        • 7.2.2.6. Bloodstream Infections
        • 7.2.2.7. Others
      • 7.2.3. Global Amebiasis Drugs by: Distribution Channel (Value)
        • 7.2.3.1. Online Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Hospital Pharmacies
      • 7.2.4. Global Amebiasis Drugs by: Site of Action (Value)
        • 7.2.4.1. Luminal Amebicides
        • 7.2.4.2. Systemic Amebicides
        • 7.2.4.3. Mixed (Luminal and Systemic) Amebicides
      • 7.2.5. Global Amebiasis Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Amebiasis Drugs (Price)
      • 7.3.1. Global Amebiasis Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Amebiasis Drugs: by Type(USD Million)
  • Table 2. Amebiasis Drugs Branded Drugs , by Region USD Million (2014-2019)
  • Table 3. Amebiasis Drugs Generic Drugs , by Region USD Million (2014-2019)
  • Table 4. Amebiasis Drugs: by Infection Type(USD Million)
  • Table 5. Amebiasis Drugs Bone Infection , by Region USD Million (2014-2019)
  • Table 6. Amebiasis Drugs Skin Infection , by Region USD Million (2014-2019)
  • Table 7. Amebiasis Drugs Ent Infections , by Region USD Million (2014-2019)
  • Table 8. Amebiasis Drugs Gastrointestinal Infection , by Region USD Million (2014-2019)
  • Table 9. Amebiasis Drugs Surgical Site Infections , by Region USD Million (2014-2019)
  • Table 10. Amebiasis Drugs Bloodstream Infections , by Region USD Million (2014-2019)
  • Table 11. Amebiasis Drugs Others , by Region USD Million (2014-2019)
  • Table 12. Amebiasis Drugs: by Distribution Channel(USD Million)
  • Table 13. Amebiasis Drugs Online Pharmacies , by Region USD Million (2014-2019)
  • Table 14. Amebiasis Drugs Retail Pharmacies , by Region USD Million (2014-2019)
  • Table 15. Amebiasis Drugs Hospital Pharmacies , by Region USD Million (2014-2019)
  • Table 16. Amebiasis Drugs: by Site of Action(USD Million)
  • Table 17. Amebiasis Drugs Luminal Amebicides , by Region USD Million (2014-2019)
  • Table 18. Amebiasis Drugs Systemic Amebicides , by Region USD Million (2014-2019)
  • Table 19. Amebiasis Drugs Mixed (Luminal and Systemic) Amebicides , by Region USD Million (2014-2019)
  • Table 20. South America Amebiasis Drugs, by Country USD Million (2014-2019)
  • Table 21. South America Amebiasis Drugs, by Type USD Million (2014-2019)
  • Table 22. South America Amebiasis Drugs, by Infection Type USD Million (2014-2019)
  • Table 23. South America Amebiasis Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 24. South America Amebiasis Drugs, by Site of Action USD Million (2014-2019)
  • Table 25. Brazil Amebiasis Drugs, by Type USD Million (2014-2019)
  • Table 26. Brazil Amebiasis Drugs, by Infection Type USD Million (2014-2019)
  • Table 27. Brazil Amebiasis Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 28. Brazil Amebiasis Drugs, by Site of Action USD Million (2014-2019)
  • Table 29. Argentina Amebiasis Drugs, by Type USD Million (2014-2019)
  • Table 30. Argentina Amebiasis Drugs, by Infection Type USD Million (2014-2019)
  • Table 31. Argentina Amebiasis Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 32. Argentina Amebiasis Drugs, by Site of Action USD Million (2014-2019)
  • Table 33. Rest of South America Amebiasis Drugs, by Type USD Million (2014-2019)
  • Table 34. Rest of South America Amebiasis Drugs, by Infection Type USD Million (2014-2019)
  • Table 35. Rest of South America Amebiasis Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 36. Rest of South America Amebiasis Drugs, by Site of Action USD Million (2014-2019)
  • Table 37. Asia Pacific Amebiasis Drugs, by Country USD Million (2014-2019)
  • Table 38. Asia Pacific Amebiasis Drugs, by Type USD Million (2014-2019)
  • Table 39. Asia Pacific Amebiasis Drugs, by Infection Type USD Million (2014-2019)
  • Table 40. Asia Pacific Amebiasis Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 41. Asia Pacific Amebiasis Drugs, by Site of Action USD Million (2014-2019)
  • Table 42. China Amebiasis Drugs, by Type USD Million (2014-2019)
  • Table 43. China Amebiasis Drugs, by Infection Type USD Million (2014-2019)
  • Table 44. China Amebiasis Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 45. China Amebiasis Drugs, by Site of Action USD Million (2014-2019)
  • Table 46. Japan Amebiasis Drugs, by Type USD Million (2014-2019)
  • Table 47. Japan Amebiasis Drugs, by Infection Type USD Million (2014-2019)
  • Table 48. Japan Amebiasis Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 49. Japan Amebiasis Drugs, by Site of Action USD Million (2014-2019)
  • Table 50. India Amebiasis Drugs, by Type USD Million (2014-2019)
  • Table 51. India Amebiasis Drugs, by Infection Type USD Million (2014-2019)
  • Table 52. India Amebiasis Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 53. India Amebiasis Drugs, by Site of Action USD Million (2014-2019)
  • Table 54. South Korea Amebiasis Drugs, by Type USD Million (2014-2019)
  • Table 55. South Korea Amebiasis Drugs, by Infection Type USD Million (2014-2019)
  • Table 56. South Korea Amebiasis Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 57. South Korea Amebiasis Drugs, by Site of Action USD Million (2014-2019)
  • Table 58. Taiwan Amebiasis Drugs, by Type USD Million (2014-2019)
  • Table 59. Taiwan Amebiasis Drugs, by Infection Type USD Million (2014-2019)
  • Table 60. Taiwan Amebiasis Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 61. Taiwan Amebiasis Drugs, by Site of Action USD Million (2014-2019)
  • Table 62. Australia Amebiasis Drugs, by Type USD Million (2014-2019)
  • Table 63. Australia Amebiasis Drugs, by Infection Type USD Million (2014-2019)
  • Table 64. Australia Amebiasis Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 65. Australia Amebiasis Drugs, by Site of Action USD Million (2014-2019)
  • Table 66. Rest of Asia-Pacific Amebiasis Drugs, by Type USD Million (2014-2019)
  • Table 67. Rest of Asia-Pacific Amebiasis Drugs, by Infection Type USD Million (2014-2019)
  • Table 68. Rest of Asia-Pacific Amebiasis Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 69. Rest of Asia-Pacific Amebiasis Drugs, by Site of Action USD Million (2014-2019)
  • Table 70. Europe Amebiasis Drugs, by Country USD Million (2014-2019)
  • Table 71. Europe Amebiasis Drugs, by Type USD Million (2014-2019)
  • Table 72. Europe Amebiasis Drugs, by Infection Type USD Million (2014-2019)
  • Table 73. Europe Amebiasis Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 74. Europe Amebiasis Drugs, by Site of Action USD Million (2014-2019)
  • Table 75. Germany Amebiasis Drugs, by Type USD Million (2014-2019)
  • Table 76. Germany Amebiasis Drugs, by Infection Type USD Million (2014-2019)
  • Table 77. Germany Amebiasis Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 78. Germany Amebiasis Drugs, by Site of Action USD Million (2014-2019)
  • Table 79. France Amebiasis Drugs, by Type USD Million (2014-2019)
  • Table 80. France Amebiasis Drugs, by Infection Type USD Million (2014-2019)
  • Table 81. France Amebiasis Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 82. France Amebiasis Drugs, by Site of Action USD Million (2014-2019)
  • Table 83. Italy Amebiasis Drugs, by Type USD Million (2014-2019)
  • Table 84. Italy Amebiasis Drugs, by Infection Type USD Million (2014-2019)
  • Table 85. Italy Amebiasis Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 86. Italy Amebiasis Drugs, by Site of Action USD Million (2014-2019)
  • Table 87. United Kingdom Amebiasis Drugs, by Type USD Million (2014-2019)
  • Table 88. United Kingdom Amebiasis Drugs, by Infection Type USD Million (2014-2019)
  • Table 89. United Kingdom Amebiasis Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 90. United Kingdom Amebiasis Drugs, by Site of Action USD Million (2014-2019)
  • Table 91. Netherlands Amebiasis Drugs, by Type USD Million (2014-2019)
  • Table 92. Netherlands Amebiasis Drugs, by Infection Type USD Million (2014-2019)
  • Table 93. Netherlands Amebiasis Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 94. Netherlands Amebiasis Drugs, by Site of Action USD Million (2014-2019)
  • Table 95. Rest of Europe Amebiasis Drugs, by Type USD Million (2014-2019)
  • Table 96. Rest of Europe Amebiasis Drugs, by Infection Type USD Million (2014-2019)
  • Table 97. Rest of Europe Amebiasis Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 98. Rest of Europe Amebiasis Drugs, by Site of Action USD Million (2014-2019)
  • Table 99. MEA Amebiasis Drugs, by Country USD Million (2014-2019)
  • Table 100. MEA Amebiasis Drugs, by Type USD Million (2014-2019)
  • Table 101. MEA Amebiasis Drugs, by Infection Type USD Million (2014-2019)
  • Table 102. MEA Amebiasis Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 103. MEA Amebiasis Drugs, by Site of Action USD Million (2014-2019)
  • Table 104. Middle East Amebiasis Drugs, by Type USD Million (2014-2019)
  • Table 105. Middle East Amebiasis Drugs, by Infection Type USD Million (2014-2019)
  • Table 106. Middle East Amebiasis Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 107. Middle East Amebiasis Drugs, by Site of Action USD Million (2014-2019)
  • Table 108. Africa Amebiasis Drugs, by Type USD Million (2014-2019)
  • Table 109. Africa Amebiasis Drugs, by Infection Type USD Million (2014-2019)
  • Table 110. Africa Amebiasis Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 111. Africa Amebiasis Drugs, by Site of Action USD Million (2014-2019)
  • Table 112. North America Amebiasis Drugs, by Country USD Million (2014-2019)
  • Table 113. North America Amebiasis Drugs, by Type USD Million (2014-2019)
  • Table 114. North America Amebiasis Drugs, by Infection Type USD Million (2014-2019)
  • Table 115. North America Amebiasis Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 116. North America Amebiasis Drugs, by Site of Action USD Million (2014-2019)
  • Table 117. United States Amebiasis Drugs, by Type USD Million (2014-2019)
  • Table 118. United States Amebiasis Drugs, by Infection Type USD Million (2014-2019)
  • Table 119. United States Amebiasis Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 120. United States Amebiasis Drugs, by Site of Action USD Million (2014-2019)
  • Table 121. Canada Amebiasis Drugs, by Type USD Million (2014-2019)
  • Table 122. Canada Amebiasis Drugs, by Infection Type USD Million (2014-2019)
  • Table 123. Canada Amebiasis Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 124. Canada Amebiasis Drugs, by Site of Action USD Million (2014-2019)
  • Table 125. Mexico Amebiasis Drugs, by Type USD Million (2014-2019)
  • Table 126. Mexico Amebiasis Drugs, by Infection Type USD Million (2014-2019)
  • Table 127. Mexico Amebiasis Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 128. Mexico Amebiasis Drugs, by Site of Action USD Million (2014-2019)
  • Table 129. Amebiasis Drugs: by Type(USD/Units)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Amebiasis Drugs: by Type(USD Million)
  • Table 142. Amebiasis Drugs Branded Drugs , by Region USD Million (2022-2027)
  • Table 143. Amebiasis Drugs Generic Drugs , by Region USD Million (2022-2027)
  • Table 144. Amebiasis Drugs: by Infection Type(USD Million)
  • Table 145. Amebiasis Drugs Bone Infection , by Region USD Million (2022-2027)
  • Table 146. Amebiasis Drugs Skin Infection , by Region USD Million (2022-2027)
  • Table 147. Amebiasis Drugs Ent Infections , by Region USD Million (2022-2027)
  • Table 148. Amebiasis Drugs Gastrointestinal Infection , by Region USD Million (2022-2027)
  • Table 149. Amebiasis Drugs Surgical Site Infections , by Region USD Million (2022-2027)
  • Table 150. Amebiasis Drugs Bloodstream Infections , by Region USD Million (2022-2027)
  • Table 151. Amebiasis Drugs Others , by Region USD Million (2022-2027)
  • Table 152. Amebiasis Drugs: by Distribution Channel(USD Million)
  • Table 153. Amebiasis Drugs Online Pharmacies , by Region USD Million (2022-2027)
  • Table 154. Amebiasis Drugs Retail Pharmacies , by Region USD Million (2022-2027)
  • Table 155. Amebiasis Drugs Hospital Pharmacies , by Region USD Million (2022-2027)
  • Table 156. Amebiasis Drugs: by Site of Action(USD Million)
  • Table 157. Amebiasis Drugs Luminal Amebicides , by Region USD Million (2022-2027)
  • Table 158. Amebiasis Drugs Systemic Amebicides , by Region USD Million (2022-2027)
  • Table 159. Amebiasis Drugs Mixed (Luminal and Systemic) Amebicides , by Region USD Million (2022-2027)
  • Table 160. South America Amebiasis Drugs, by Country USD Million (2022-2027)
  • Table 161. South America Amebiasis Drugs, by Type USD Million (2022-2027)
  • Table 162. South America Amebiasis Drugs, by Infection Type USD Million (2022-2027)
  • Table 163. South America Amebiasis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 164. South America Amebiasis Drugs, by Site of Action USD Million (2022-2027)
  • Table 165. Brazil Amebiasis Drugs, by Type USD Million (2022-2027)
  • Table 166. Brazil Amebiasis Drugs, by Infection Type USD Million (2022-2027)
  • Table 167. Brazil Amebiasis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 168. Brazil Amebiasis Drugs, by Site of Action USD Million (2022-2027)
  • Table 169. Argentina Amebiasis Drugs, by Type USD Million (2022-2027)
  • Table 170. Argentina Amebiasis Drugs, by Infection Type USD Million (2022-2027)
  • Table 171. Argentina Amebiasis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 172. Argentina Amebiasis Drugs, by Site of Action USD Million (2022-2027)
  • Table 173. Rest of South America Amebiasis Drugs, by Type USD Million (2022-2027)
  • Table 174. Rest of South America Amebiasis Drugs, by Infection Type USD Million (2022-2027)
  • Table 175. Rest of South America Amebiasis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 176. Rest of South America Amebiasis Drugs, by Site of Action USD Million (2022-2027)
  • Table 177. Asia Pacific Amebiasis Drugs, by Country USD Million (2022-2027)
  • Table 178. Asia Pacific Amebiasis Drugs, by Type USD Million (2022-2027)
  • Table 179. Asia Pacific Amebiasis Drugs, by Infection Type USD Million (2022-2027)
  • Table 180. Asia Pacific Amebiasis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 181. Asia Pacific Amebiasis Drugs, by Site of Action USD Million (2022-2027)
  • Table 182. China Amebiasis Drugs, by Type USD Million (2022-2027)
  • Table 183. China Amebiasis Drugs, by Infection Type USD Million (2022-2027)
  • Table 184. China Amebiasis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 185. China Amebiasis Drugs, by Site of Action USD Million (2022-2027)
  • Table 186. Japan Amebiasis Drugs, by Type USD Million (2022-2027)
  • Table 187. Japan Amebiasis Drugs, by Infection Type USD Million (2022-2027)
  • Table 188. Japan Amebiasis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 189. Japan Amebiasis Drugs, by Site of Action USD Million (2022-2027)
  • Table 190. India Amebiasis Drugs, by Type USD Million (2022-2027)
  • Table 191. India Amebiasis Drugs, by Infection Type USD Million (2022-2027)
  • Table 192. India Amebiasis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 193. India Amebiasis Drugs, by Site of Action USD Million (2022-2027)
  • Table 194. South Korea Amebiasis Drugs, by Type USD Million (2022-2027)
  • Table 195. South Korea Amebiasis Drugs, by Infection Type USD Million (2022-2027)
  • Table 196. South Korea Amebiasis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 197. South Korea Amebiasis Drugs, by Site of Action USD Million (2022-2027)
  • Table 198. Taiwan Amebiasis Drugs, by Type USD Million (2022-2027)
  • Table 199. Taiwan Amebiasis Drugs, by Infection Type USD Million (2022-2027)
  • Table 200. Taiwan Amebiasis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 201. Taiwan Amebiasis Drugs, by Site of Action USD Million (2022-2027)
  • Table 202. Australia Amebiasis Drugs, by Type USD Million (2022-2027)
  • Table 203. Australia Amebiasis Drugs, by Infection Type USD Million (2022-2027)
  • Table 204. Australia Amebiasis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 205. Australia Amebiasis Drugs, by Site of Action USD Million (2022-2027)
  • Table 206. Rest of Asia-Pacific Amebiasis Drugs, by Type USD Million (2022-2027)
  • Table 207. Rest of Asia-Pacific Amebiasis Drugs, by Infection Type USD Million (2022-2027)
  • Table 208. Rest of Asia-Pacific Amebiasis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 209. Rest of Asia-Pacific Amebiasis Drugs, by Site of Action USD Million (2022-2027)
  • Table 210. Europe Amebiasis Drugs, by Country USD Million (2022-2027)
  • Table 211. Europe Amebiasis Drugs, by Type USD Million (2022-2027)
  • Table 212. Europe Amebiasis Drugs, by Infection Type USD Million (2022-2027)
  • Table 213. Europe Amebiasis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 214. Europe Amebiasis Drugs, by Site of Action USD Million (2022-2027)
  • Table 215. Germany Amebiasis Drugs, by Type USD Million (2022-2027)
  • Table 216. Germany Amebiasis Drugs, by Infection Type USD Million (2022-2027)
  • Table 217. Germany Amebiasis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 218. Germany Amebiasis Drugs, by Site of Action USD Million (2022-2027)
  • Table 219. France Amebiasis Drugs, by Type USD Million (2022-2027)
  • Table 220. France Amebiasis Drugs, by Infection Type USD Million (2022-2027)
  • Table 221. France Amebiasis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 222. France Amebiasis Drugs, by Site of Action USD Million (2022-2027)
  • Table 223. Italy Amebiasis Drugs, by Type USD Million (2022-2027)
  • Table 224. Italy Amebiasis Drugs, by Infection Type USD Million (2022-2027)
  • Table 225. Italy Amebiasis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 226. Italy Amebiasis Drugs, by Site of Action USD Million (2022-2027)
  • Table 227. United Kingdom Amebiasis Drugs, by Type USD Million (2022-2027)
  • Table 228. United Kingdom Amebiasis Drugs, by Infection Type USD Million (2022-2027)
  • Table 229. United Kingdom Amebiasis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 230. United Kingdom Amebiasis Drugs, by Site of Action USD Million (2022-2027)
  • Table 231. Netherlands Amebiasis Drugs, by Type USD Million (2022-2027)
  • Table 232. Netherlands Amebiasis Drugs, by Infection Type USD Million (2022-2027)
  • Table 233. Netherlands Amebiasis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 234. Netherlands Amebiasis Drugs, by Site of Action USD Million (2022-2027)
  • Table 235. Rest of Europe Amebiasis Drugs, by Type USD Million (2022-2027)
  • Table 236. Rest of Europe Amebiasis Drugs, by Infection Type USD Million (2022-2027)
  • Table 237. Rest of Europe Amebiasis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 238. Rest of Europe Amebiasis Drugs, by Site of Action USD Million (2022-2027)
  • Table 239. MEA Amebiasis Drugs, by Country USD Million (2022-2027)
  • Table 240. MEA Amebiasis Drugs, by Type USD Million (2022-2027)
  • Table 241. MEA Amebiasis Drugs, by Infection Type USD Million (2022-2027)
  • Table 242. MEA Amebiasis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 243. MEA Amebiasis Drugs, by Site of Action USD Million (2022-2027)
  • Table 244. Middle East Amebiasis Drugs, by Type USD Million (2022-2027)
  • Table 245. Middle East Amebiasis Drugs, by Infection Type USD Million (2022-2027)
  • Table 246. Middle East Amebiasis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 247. Middle East Amebiasis Drugs, by Site of Action USD Million (2022-2027)
  • Table 248. Africa Amebiasis Drugs, by Type USD Million (2022-2027)
  • Table 249. Africa Amebiasis Drugs, by Infection Type USD Million (2022-2027)
  • Table 250. Africa Amebiasis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 251. Africa Amebiasis Drugs, by Site of Action USD Million (2022-2027)
  • Table 252. North America Amebiasis Drugs, by Country USD Million (2022-2027)
  • Table 253. North America Amebiasis Drugs, by Type USD Million (2022-2027)
  • Table 254. North America Amebiasis Drugs, by Infection Type USD Million (2022-2027)
  • Table 255. North America Amebiasis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 256. North America Amebiasis Drugs, by Site of Action USD Million (2022-2027)
  • Table 257. United States Amebiasis Drugs, by Type USD Million (2022-2027)
  • Table 258. United States Amebiasis Drugs, by Infection Type USD Million (2022-2027)
  • Table 259. United States Amebiasis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 260. United States Amebiasis Drugs, by Site of Action USD Million (2022-2027)
  • Table 261. Canada Amebiasis Drugs, by Type USD Million (2022-2027)
  • Table 262. Canada Amebiasis Drugs, by Infection Type USD Million (2022-2027)
  • Table 263. Canada Amebiasis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 264. Canada Amebiasis Drugs, by Site of Action USD Million (2022-2027)
  • Table 265. Mexico Amebiasis Drugs, by Type USD Million (2022-2027)
  • Table 266. Mexico Amebiasis Drugs, by Infection Type USD Million (2022-2027)
  • Table 267. Mexico Amebiasis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 268. Mexico Amebiasis Drugs, by Site of Action USD Million (2022-2027)
  • Table 269. Amebiasis Drugs: by Type(USD/Units)
  • Table 270. Research Programs/Design for This Report
  • Table 271. Key Data Information from Secondary Sources
  • Table 272. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Amebiasis Drugs: by Type USD Million (2014-2019)
  • Figure 5. Global Amebiasis Drugs: by Infection Type USD Million (2014-2019)
  • Figure 6. Global Amebiasis Drugs: by Distribution Channel USD Million (2014-2019)
  • Figure 7. Global Amebiasis Drugs: by Site of Action USD Million (2014-2019)
  • Figure 8. South America Amebiasis Drugs Share (%), by Country
  • Figure 9. Asia Pacific Amebiasis Drugs Share (%), by Country
  • Figure 10. Europe Amebiasis Drugs Share (%), by Country
  • Figure 11. MEA Amebiasis Drugs Share (%), by Country
  • Figure 12. North America Amebiasis Drugs Share (%), by Country
  • Figure 13. Global Amebiasis Drugs: by Type USD/Units (2014-2019)
  • Figure 14. Global Amebiasis Drugs share by Players 2019 (%)
  • Figure 15. Global Amebiasis Drugs share by Players (Top 3) 2019(%)
  • Figure 16. Global Amebiasis Drugs share by Players (Top 5) 2019(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Dr. Reddy's Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 19. Dr. Reddy's Laboratories (India) Revenue: by Geography 2019
  • Figure 20. Mission Pharmacal (United States) Revenue, Net Income and Gross profit
  • Figure 21. Mission Pharmacal (United States) Revenue: by Geography 2019
  • Figure 22. Aceto Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 23. Aceto Corporation (United States) Revenue: by Geography 2019
  • Figure 24. Mylan Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 25. Mylan Pharmaceuticals (United States) Revenue: by Geography 2019
  • Figure 26. Impax Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 27. Impax Laboratories (United States) Revenue: by Geography 2019
  • Figure 28. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 29. Pfizer (United States) Revenue: by Geography 2019
  • Figure 30. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 31. Sanofi (France) Revenue: by Geography 2019
  • Figure 32. Lupin Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 33. Lupin Pharmaceuticals (India) Revenue: by Geography 2019
  • Figure 34. Glenmark Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 35. Glenmark Pharmaceuticals (India) Revenue: by Geography 2019
  • Figure 36. Sun Pharmaceutical (India) Revenue, Net Income and Gross profit
  • Figure 37. Sun Pharmaceutical (India) Revenue: by Geography 2019
  • Figure 38. Heritage Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 39. Heritage Pharmaceuticals (United States) Revenue: by Geography 2019
  • Figure 40. Global Amebiasis Drugs: by Type USD Million (2022-2027)
  • Figure 41. Global Amebiasis Drugs: by Infection Type USD Million (2022-2027)
  • Figure 42. Global Amebiasis Drugs: by Distribution Channel USD Million (2022-2027)
  • Figure 43. Global Amebiasis Drugs: by Site of Action USD Million (2022-2027)
  • Figure 44. South America Amebiasis Drugs Share (%), by Country
  • Figure 45. Asia Pacific Amebiasis Drugs Share (%), by Country
  • Figure 46. Europe Amebiasis Drugs Share (%), by Country
  • Figure 47. MEA Amebiasis Drugs Share (%), by Country
  • Figure 48. North America Amebiasis Drugs Share (%), by Country
  • Figure 49. Global Amebiasis Drugs: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Dr. Reddy's Laboratories (India)
  • Mission Pharmacal (United States)
  • Aceto Corporation (United States)
  • Mylan Pharmaceuticals (United States)
  • Impax Laboratories (United States)
  • Pfizer (United States)
  • Sanofi (France)
  • Lupin Pharmaceuticals (India)
  • Glenmark Pharmaceuticals (India)
  • Sun Pharmaceutical (India)
  • Heritage Pharmaceuticals (United States)
Select User Access Type

Key Highlights of Report


Jul 2022 155 Pages 50 Tables Base Year: 2019 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Amebiasis Drugs Quantitative research analysis
Global Amebiasis Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Amebiasis Drugs Market is heading robustly to achieve a new growth cycle.
The Concentration Rate of Global Amebiasis Drugs market is dominated by United States Players and may generate healthy valuation by 2027.
  • Increasing Prevalence of Parasitic Infections
  • The Increasing Pool of Patients Suffering from Amebic Infections
dominated the Amebiasis Drugs market. This is attributable to growing trend of "The Rising Level of Awareness "

Know More About Global Amebiasis Drugs Report?

Have a Query? Click Here

Other Related Reports

Neuralgia Patches Comprehensive Study by Type (Capsaicin Skin Patches, Lidocaine Skin Patches), Application (Back Pain, Neck Pain, Shoulder Pain, Knees & Elbow Pain, Others), Distribution Channel (On...
$ 3450
Zoledronic Acid Comprehensive Study by Type (Injection, Powder), Application (Metastatic Bone Cancers, Systemic Metabolic Bone Diseases, Osteoporosis, Paget Disease), Dose Type (4mg, 3.5mg, 3.3mg, 3m...
$ 3500
Women Nutrition Comprehensive Study by Type (Sports Nutrition, Additional Supplements, Personalised Nutrition, Others), Products (Vitamins, Minerals, Enzymes, Botanicals, Proteins, Omega-3, Probiotic...
$ 3650
N95 Masks Comprehensive Study by Type (With Exhalation Valve, Without Exhalation Valve), Application (Healthcare, Construction, Manufacturing, Mining, Oil & Gas, Others), By Usablity (Standard N95 Re...
$ 3750
Absorbent Foam Dressing Comprehensive Study by Type (Without Adhesive Border, With Adhesive Border), Application (Chronic Wounds, Acute Wounds, Lower Extremity Ulcers, Pressure Ulcers, Low Exuding Wo...
$ 3750
Ketone Supplements Comprehensive Study by Type (Ketone salts, Ketone esters, Ketone oil, Raspberry ketones), Form (Solid, Liquid & semi-liquid), Distribution Channel (Online, Offline) Players and Reg...
$ 3500